40例甲磺酸阿帕替尼不良反应评价分析

doi:10.19803/j.1672-8629.2019.12.07

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (12): 741-746.
DOI: 10.19803/j.1672-8629.2019.12.07

• 安全性评价与合理用药 • 上一篇下一篇

40例甲磺酸阿帕替尼不良反应评价分析

张夏兰, 沈夕坤^*, 吴斌

苏州市中医医院药学部,江苏苏州 215009

收稿日期:2019-12-18 修回日期:2019-12-18 出版日期:2019-12-15 发布日期:2019-12-18
通讯作者: *沈夕坤,男,副教授,主任中药师,中药临床药学。 E-mail：sxkzxy@163.com
作者简介:张夏兰,女,硕士学位,副主任药师,抗肿瘤临床药学。

Analysis of 40 Cases of Adverse Reactions to Apatinib Mesylate

ZHANG Xialan, SHEN Xikun^*, WU Bin

Department of Pharmacy, Suzhou Hospital of Traditional Chinese Medicine, Suzhou Jiangsu 215009, China

Received:2019-12-18 Revised:2019-12-18 Online:2019-12-15 Published:2019-12-18

摘要/Abstract

摘要： 目的总结甲磺酸阿帕替尼致药品不良反应的特点,为安全合理用药提供参考。方法对40例服用阿帕替尼出现不良反应的患者性别、年龄、临床诊断、既往不良反应史、服药剂量、服药频次、不良反应累积器官-系统及临床表现、不良反应发生时间、处理和预后等信息进行统计分析。结果老年男性更易发生阿帕替尼所致不良反应;不良反应主要症状为血压升高、胃肠道反应、乏力、肝功能异常、皮肤损伤等;一般不良反应22例,严重不良反应18例。结论应重视阿帕替尼药品不良反应监测,提高用药安全性。

关键词: 阿帕替尼, 药品不良反应, 合理用药

Abstract: Objective To summarize the characteristics of adverse drug reactions caused by apatinib mesylate and provide data for safe and rational medication. Methods The gender, age, clinical diagnosis, history of adverse reactions, dosage, frequency of administration, organs or systems involved, clinical manifestations, time of occurrence, treatment and prognosis of adverse reactions were statistically analyzed among 40 patients with apatinib-caused adverse reactions. Results Elder males were more vulnerable to adverse reactions caused by apatinib. The main symptoms of adverse reactions included elevated blood pressure, gastrointestinal reactions, fatigue, abnormal liver function and skin lesion. There were 22 cases of mild adverse reactions and 18 cases of serious adverse reactions. Conclusion Adverse drug reactions caused by apatinib should be more effectively monitored to improve the safety of medication.

Key words: apatinib, adverse drug reaction, rational medication

中图分类号:

R994.11

张夏兰, 沈夕坤, 吴斌. 40例甲磺酸阿帕替尼不良反应评价分析[J]. 中国药物警戒, 2019, 16(12): 741-746.

ZHANG Xialan, SHEN Xikun, WU Bin. Analysis of 40 Cases of Adverse Reactions to Apatinib Mesylate[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 741-746.

参考文献

[1] Shu T, H Q, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Science, 2011, 102(7):1374-1380.
[2] Haijun Z .Apatinib for molecular targeted therapy in tumor[J]. Drug Design, Development and Therapy, 2015, (9):6075-6081.
[3] Hu X, Cao J, Hu W, et al.Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer, 2014, 14(1):820.
[4] Li J, Qin S, Xu J, et al.Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial[J]. Journal of Clinical Oncology, 2013, 31(26):3219-3225.
[5] 李红颖, 杨翠平, 靳洪涛. 抗肿瘤药物的靶点毒性研究进展[J]. 中国药物警戒, 2018, 15(3):152-157.
[6] 左婷婷, 郑荣寿, 曾红梅,等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1):52-58.
[7] Yu M, Gao Z, Dai X, et al.Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors[J]. Clinical Pharmacokinetics, 2017, 56(1):65-76.
[8] Li J, Qin S, Xu J, et al.Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial[J]. Journal of Clinical Oncology, 2013, 31(26):3219-3225.
[9] Huang L, Wei Y, Shen S, et al.Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients[J]. Oncotarget, 2017 ,8(17):29346-29354.
[10] Liao X, Li H, Liu Z, et al.Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine (Baltimore), 2018,97(50): e13635.
[11] Miao M, Deng G, Luo S, et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].GynecolOncol, 2018, 148(2):286-290.
[12] Wang L, Liang L, Yang T, et al.A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study[J]. Medicine,2017, 96(49): e9053.
[13] Hu X, Cao J, Hu W, et al.Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer, 2014, 14(1):820.
[14] Lu W, Jin X L, Yang C, et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J].Cancer Biology & Therapy, 2017, 18(6):433-438.
[15] Li J,Qin S, Xu J, et al .Apatinib for chemotherapy-re fractory advanced metastatic gastric cancer: results from a randomized placebo-controlled, parallel-arm, phase II trial[J]. J clin Oncol,2013,31(26):3219-3225.
[16] Hu X, Zhang J, Xu B, et al.Multicenter Phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple negative breast cancer[J].International Journal of Cancer, 2014, 135(8):1961-1969.
[17] Liao X, Li H, Liu Z, et al.Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine, 2018, 97(50):e13635.
[18] Miao M, Deng G, Luo S, et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.
[19] Wang L, Liang L, Yang T, et al.A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma[J]. Medicine, 2017, 96(49):e9053.
[20] Reddy G K, Jain V K .The Addition of Bevacizumab to FOLFOX4 Prolongs Survival in Relapsed Colorectal Cancer:Interim Data from the ECOG 3200 Trial[J]. Clinical Colorectal Cancer, 2005, 4(5):300-301.
[21] Scott A J, Messersmith W A, Jimeno A .Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J]. Drugs of Today, 2015, 51(4):223-239.
[22] Tian S, Quan H, Xie C, et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Science, 2011, 102(7):1374-1380.
[23] Lan CY, Wang Y, Xiong Y,et al.Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2,single-arm, prospective study. Lancet Oncol,2018,19(9):1239-1246.
[24] Bollee G, Patey N, Cazajous G, et al.Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib[J]. Nephrology Dialysis Transplantation, 2008,24(2):682-685.
[25] Li J, Qin S, Xu J, et al.Randomized, Double-Blind,Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[J]. Journal of Clinical Oncology, 2016, 34(13):1448-1454.

40例甲磺酸阿帕替尼不良反应评价分析

Analysis of 40 Cases of Adverse Reactions to Apatinib Mesylate

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[3]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[4]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[5]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[6]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.